Literature DB >> 10380095

Relation between pulse oximetry and clinical score in children with acute wheezing less than 24 months of age.

D Pavón1, J A Castro-Rodríguez, L Rubilar, G Girardi.   

Abstract

The aim of this study was to determine the relation between transcutaneous hemoglobin oxygen saturation, measured by pulse oximetry (SpO2), and clinical score values in 138 infants (mean+/-SD, 6.6+/-5.5 months of age) with acute wheezing episodes presenting in a primary care outpatient setting. A single investigator evaluated the severity of the acute wheezing episodes by assigning a clinical score and was unaware of the SpO2 values. Another investigator measured SpO2 values on all subjects. The mean (+/-SD) SpO2 value was 98.2+/-1.1% for children with clinical scores of 2-5 (n = 32); 95.4+/-1.5% for those with scores of 6-7 (n = 82), and 92.9+/-2% for children with scores of 8-10 (n = 24), (P < 0.001 by Bonferroni's multiple comparison, when all two-way comparisons were done for each pair of results). The clinical score showed a good correlation with SpO2 (r = -0.76; 95% CI, -0.83 to -0.68). We conclude that if pulse oximetry is not available, it is advisable to include oxygen in the therapy of wheezy infants with clinical scores values >8.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10380095     DOI: 10.1002/(sici)1099-0496(199906)27:6<423::aid-ppul10>3.0.co;2-5

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  2 in total

Review 1.  Nebulizers versus pressurized metered-dose inhalers in preschool children with wheezing.

Authors:  Christine Smith; Ran D Goldman
Journal:  Can Fam Physician       Date:  2012-05       Impact factor: 3.275

2.  Field testing two existing, standardized respiratory severity scores (LIBSS and ReSViNET) in infants presenting with acute respiratory illness to tertiary hospitals in Rwanda - a validation and inter-rater reliability study.

Authors:  Boniface Hakizimana; Edgar Kalimba; Augustin Ndatinya; Gemma Saint; Clare van Miert; Peter Thomas Cartledge
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.